Deuruxolitinib

Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata[1].

Product Specifications

CAS Number

[1513883-39-0]

Product Name Alternative

CTP-543; Ruxolitinib D8; Deuterated Ruxolitinib

UNSPSC

12352005

Target

JAK

Type

Isotope-Labeled Compounds

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Purity

99.18

Solubility

DMSO : 116.67 mg/mL (ultrasonic)

Smiles

N#CC[C@@H](N1N=CC(C2=C3C(NC=C3)=NC=N2)=C1)C4C([2H])(C([2H])(C([2H])(C4([2H])[2H])[2H])[2H])[2H]

Molecular Formula

C17H10D8N6

Molecular Weight

314.41

References & Citations

[1]Brett King, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1) . J Am Acad Dermatol. 2024 Nov;91 (5) :880-888.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.